Archive
Report of Eurocan Plus: feasibility study for the co-ordination of national cancer research
Peter Boyle on behalf of project participants Eurocan Plus
The process that led the presentation and the financing of the project: Eurocan + Plus from the sixth framework programme was launched by the European Parliament.
This report summarises the main findings and conclusions of the Eurocan + Plus project that ran between October 2005 and December 2007, and outlines the proposals for action in the short and long term.
Project participants represented themselves and not the institution where they work.The project was in no way a formal collaboration between any governmental body, funding agency, research or medical institution of the 27 Member States. in this regard, proposals in this brief and other deliverables in no way constitute a formal commitment all governmental or nongovernmental entity, for any idea proposed by the project.
For more information about the topics developed in this report, interested readers are invited to consult the reports of the different work packages. these reports can be consulted on the draft http://www.eurocanplus.eu website.
Volume: 2 article number: 84 DOI: 10.3332/eCMS. 2008.84 received: 09/05/2008 published: 20/05/2008
To view this article in its entirety, you must first sign in or register.
The impact of decision models on the perception of quality of life: a study on the brain of patients of cancer
C. Lucchiari, Boturri, g. Pravettoni
Quality of life (QoL) is an important measure increasing result in medicine. Health is not only State-based, functional, but also psychological and social well-being. Since QoL is linked to the patient’s perception of their position in life towards their objectives, expectations, standards and concerns (Bottomley, 2002), the way you lived the medical context can be critical. We then hypothesizes that self perceived that QoL can be linked to unmet needs in the involvement of management and the decision of information. Analyze this hypothesis that we conducted a quantitative study on 84 consecutive patients with a primary diagnosis of glioma of high quality.The stairs of notes-Br, scale HAD and the questionnaire NEQ were used in order to measure the size of the quality of life, humor and unmet. patients were classified as having any need (cluster a), a moderate need (cluster two) or a high need (cluster of three) to be more involved in the clinical process.
Our data confirmed previous studies in other clinical areas, showing that the decision to share could contribute to a process of adapting better to the disease (Hubbard, Kidd & Donaghy, 2008).In fact, patients in one cluster showed a significant self perceived better QoL, despite the absence of clinical differences between clusters.The study showed that patients satisfied with regard to the decision-making involvement appear to be able to cope with their illness. Finally, the study suggests that a decision-making more attuned to approaching clinical decisions. physicians must better understand the patient’s preferences concerning the information and sharing decision.
Volume: 4 article number: 187 DOI: 10.3332/ecancer. 2010.187 received: 17/05/2010 published: 20/08/2010
To view this article in its entirety, you must first sign in or register.
Syzygium Cumini inhibits the growth and induces apoptosis in cancer cell lines of cervix: main study
D. Barh, g. Viswanathan
Cervical cancer is common among women in the Indian subcontinent and the incidence and mortality rates are gradually increasing over the years. Different dietary phytochemicals are reported growth inhibitory and apoptotic effect HeLa and other cervical cell lines.In this study, using Hoechst 33342 colouring, MTT, Annexin V/PI-FLUOS and TUNEL assays that we have shown that Syzygium Cumini Extract inhibits the growth and that induces apoptosis in cancer cell lines HeLa cervical and SiHa dependently dose and time. The phytochemical, its mode of action and security problems are still to be determined.
Volume: 2 article number: 83 DOI: 10.3332/ecancer. 2008.83 received: 29/04/2008 published: 08/21/2008
To view this article in its entirety, you must first sign in or register.
A randomized prospective study and tocopherol Pentoxifylline extended beyond therapy, Carbogen, treatment of Radiation Effects end
S. Brennan, o. Hill cross, c. o’ Shea, m. Moriarty
Purpose: Pentoxifylline (PTX) and tocopherol (vitamin e) are antioxidants previously proved to be useful in combination in the treatment of radiation-induced toxicity of late.The purpose of this study was to investigate the benefit of combination therapy with carbogen pentoxifylline and tocopherol in mitigation of late As the radiation. optimal duration of treatment PTX and tocopherol has not been fully established, we studied short against prolonged the duration of treatment.
Methods: we conducted a phase II randomized prospective study of short versus prolonged treatment with pentoxifylline (800 mg) and tocopherol (1000 IU) orally once daily in patients with grade 3 toxicity post radical radiotherapy. in addition, all 18 patients received inhaled carbogen (95% oxygen + 5% CO2) over 90 minutes, 5 days a week, for 3 weeks.The primary endpoint was improved maximum scores of toxicity of lent-soma.
Results: Massimo lent-Soma scores improved in six eighteen patients (response rate: 33%). the proportion of patients responding to treatment in prolonged treatment arm B was more than double short arm, but this did not reach statistical significance (p 0317). two patients who had prolonged treatment (arm B) had complete resolution of their symptoms, which was kept at 2 and 3 years of follow-up.
Conclusions: we recommend a treatment extended to 12 months, with PTX and tocopherol in combination with carbogen, therapy in the management of late radiation effects.
Volume: 2 article number: 81 DOI: 10.3332/eCMS. 2008.81 received: 21/04/2008 published: 09/06/2008
To view this article in its entirety, you must first sign in or register.
A study of the corresponding group of triple negative positive cancer (regardless of the status hormonal) HER-2: two subtypes with high-risk functionality and poor results
J. m. Ibrahim Zekri, e., b. b. Sadiq, r. m. al-Gahmi, r. r. Zeeneldin, t. r. Elkhodary, h. e. Gaballa, e. e. Fawzy, m. e. Elsayed, y. Bahadur, s. Awadalla, m. s. Alzahran
Introduction: Studies of genetic profile of breast cancer has identified a number of biologically different subtypes. These surrogate genetic subtypes are often from estrogen receptors (ER), progesterone receptor (PR) and of the HER2 status, as measured by Immunohistochemistry (IHC). Triple negative subtype (TN) is acknowledged to have high-risk functionality and poor result.Overexpression of HER2 is also recognized as a result of poor marker. The characteristics and results of HER2-positive tumours (regardless of the status hormonal) (HR HER2 +/-) identified by IHC haven’t tackled in the era of surrogate genetic subtype. Therefore, we compared a posteriori hazard characteristics and clinical results of patients with TN against these with AR HER2 +/-tumori.
Patients and methods: forty patients with AR HER2 +/-tumori were matched for age and stage of 40 patients with tumours TN. pathological and clinical data were collected retrospectively. All patients were managed in a single institution.
Results: degree of tumor and phase and frequency of pathologically involved lymph nodes were similar in both groups. There was a tendency more HER2 + lymphovascular invasion HR/-rispetto to patients TN (40% vs. 27.5%.P = 0.07).Were not statistically different rates of death and relapse (P = 0469 and P = 1.0 respectively).Median relapse-free survival was 38 months for TN and not achieved for now HER2 +/-pazienti (register of rank; P = 0757). average overall survival was not met in both groups. multivariate analysis not have identified TN or time of HER2 +/-stato to have a differential impact on RFS.
Conclusion: HR HER2 +/-tumori expose high risk characteristics and relatively poor clinical results probably not much different from tumor TN increasingly recognised.
Volume: 4 article number: 167 DOI: 10.3332/ecancer. 2010.167 received: 17/11/2009 published: 27/08/2010
To view this article in its entirety, you must first sign in or register.
LigaSure (TM) reduces fluid drainage in axillary dissection? A prospective randomized clinical study
Antonio m., t. Stone, L.G. Domenico, d., r. Ignatius, n. Anthony, Louis c.
Background-lymph node axillary dissection (ALND) is an integral part of the treatment of breast cancer. It is mandatory in approximately 60% of patients. Place a drain in the armpit after an operation is current surgical practice. Short stay surgical programs increase operational efficiency and reduce cost of medical care, without compromising the quality of care.LigaSureTM is a new device that uses energy Haemostatic bipolar for sealing vessels. the purpose of this study was to determine whether the axillary dissection with LigaSureTM reduces wound drainage, the duration of surgery and the volume of drainage after treatment.
patients and methods of this study is a prospective randomized controlled trial.100 women with breast cancer, who needed to axillary dissection were randomized into LigaSureTM or group of conventional axillary dissection. lymph node dissection level III was executed. A closed suction drain was always placed in the armpit and removed after 6-8 days or when was the amount of fluid
Results there are significant differences between the two groups when considering the duration of the surgical procedure: average duration was 70.7 24.66 minutes for patients of LigaSureTM, whereas in conventional dissection group the average was 70.6 22.47 minutes (p = 0,98). total amount of fluid drained was 624.49 cc in axillary dissection LigaSureTM and 792.96 ALND conventional group; this difference did not reach statistical significance (p = 0.09); the duration of drainage also was similar with no statistical difference (p = 0.15).
Conclusions of this study were not showing clear advantages in using for ALND LigaSureTM, although it is a good device Haemostatic, especially in abdominal Surgery.
Keyword breast cancer;breast cancer surgery; axillary dissection; Seroma; discharge; hemostasis; LigaSure.
Volume: 1 article number: 61 DOI: 10.3332/eCMS. 2007.61 received: 02/10/2007 published: 29/11/2007
To view this article in its entirety, you must first sign in or register.
Comparative analysis of survival of breast cancer microarray study identifies important predictive genetic journey
About 12% of women in the United States will develop breast cancer in their lifetime. Despite the fact that there have been advances in treatment, including therapy and chemotherapy, breast cancer remains the second most deadly types of cancer in women. Thus, there is a clear need for improved prediction of prognosis of breast cancer for every patient. With the advent of large genetic databases and reduce costs for experiments researchers are faced with choices from a large number of potential prognostic markers of breast Cancer gene expression numerous profile study.
Five microarray data sets associated with breast cancer were examined using a set of gene analysis and crayfish have been grouped under different subtypes, using a scoring system based on genetic path.
We note that significant genes in separate studies show a little reproducibility between datasets.From our comparative analysis using gene pathways clinical variables is more reliable and promising research to assess patient prognosis.
The study concluded that in light of clinical variables, there are significant gene pathways between datasets in particular several paths you can considerably further stratify patients survival. Pathways to help develop these candidates has a large group of biomarkers for prognosis of breast cancer patients in the clinical setting.
cancer3 